Filing summary
Entity and period: The supplied filing is Senesco Technologies, Inc.’s Form 10-K for the fiscal year ended June 30, 2014, signed September 29, 2014. It is not an Eloxx Pharmaceuticals filing and does not report a 2013 fourth quarter; the requested company and period therefore do not match the source.
Business context
Senesco was a development-stage biotechnology company focused on cancer and inflammatory-disease therapeutics, using Factor 5A gene-regulation technology and antibody discovery platforms. Its lead gene-therapy candidate, SNS01-T, was in a Phase 1b/2a study for B-cell cancers. SVN001 and SVN002 were preclinical antibody candidates. The company had no commercialized products and expected limited revenue for several years.
On May 16, 2014, Senesco acquired antibody-platform developer Fabrus for stock, warrants and options valued at approximately $20.9 million. In September 2014, after the fiscal year-end, the company began changing its name to Sevion Therapeutics, Inc.
Financial results and liquidity
| Metric | FY ended June 30, 2014 | FY ended June 30, 2013 |
|---|---|---|
| Revenue | $100,000 | $0 |
| Operating expenses | $9.25 million | $4.65 million |
| Operating loss | $9.15 million | $4.65 million |
| Net loss | $9.23 million | $6.12 million |
| Loss applicable to common shares | $13.85 million | $6.99 million |
| Basic and diluted loss per share | $2.53 | $5.11 |
| Cash and cash equivalents at year-end | $6.11 million | $1.60 million |
| Working capital at year-end | $5.40 million | $0.31 million |
| Total assets / total liabilities | $33.33 million / $5.84 million | $7.10 million / $3.31 million |
Revenue was a milestone payment under an agricultural license. FY2014 operating expenses rose 98.9%, including higher R&D and general and administrative costs, $545,000 of acquisition costs, a $1.35 million agricultural-patent impairment, and $330,000 of abandoned-patent write-offs. The filing gives no meaningful product margin; the company had no commercial product sales.
Operating cash use was $4.87 million; investing activities provided $647,000, including $1.27 million cash acquired with Fabrus; financing activities provided $8.73 million, primarily from stock and warrant issuances/exercises, partly offset by repayment of the $2.19 million line of credit. The line was repaid and cancelled in February 2014; year-end balance was zero. The filing reports no other material debt balance.
Material changes and unusual items
- Fabrus contributed acquired in-process R&D valued at $9.8 million and goodwill of $13.9 million. FY2014 results include Fabrus only from May 16 through June 30; unaudited pro forma combined revenue and net loss were $182,229 and $11.02 million, respectively.
- Senesco recorded $4.63 million in preferred dividends for FY2014, including noncash deemed dividends associated with warrant amendments. Consequently, loss applicable to common shares materially exceeded net loss.
- The agricultural patent portfolio was fully impaired for its $1.35 million carrying value. Bayer returned rights to agricultural applications in November 2013; Monsanto notified the company in July 2014 that it would stop further development absent additional progress. The BCV agreement was terminated after breach, and Dow AgroSciences discontinued alfalfa development; other partner prospects were uncertain.
- Cash increased year over year, largely following equity financing, but common shares outstanding increased from 2.27 million to 13.85 million, including 6.91 million shares issued for Fabrus. The filing also reports 7.24 million outstanding warrants and 979,304 options at June 30, 2014.
Outlook, risks and contingencies
Management said cash was expected to fund operations through at least March 31, 2015 and planned to seek additional equity or debt capital and licensing arrangements. However, the financial-statement note says cash was not adequate for anticipated expenses over the next 12 months. The auditor’s report and the company’s disclosures identify substantial doubt about the ability to continue as a going concern. Additional financing was not assured; without it, the company could curtail programs, license assets, seek a transaction, cease operations or seek bankruptcy protection.
The SNS01-T study reported stable disease at end of treatment in 4 of 10 evaluable patients in the first three cohorts. In August 2014, after year-end, a second dose-limiting toxicity in the highest-dose cohort established the maximum tolerated dose; recruitment was complete, and enrolled patients could continue at the recommended 0.2 mg/kg dose. The filing describes preclinical combination results for SNS01-T with approved cancer drugs, but these results do not establish clinical benefit. The company anticipated further development and possible partnering, subject to financing and successful research and regulatory progress.
Key risks include recurring losses and cash burn, dependence on future financing, clinical and regulatory failure, reliance on external research and manufacturing partners, patent and licensing risks, intense competition, dilution, and limited OTCQB trading liquidity. The company reported no current legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the filing identity and fiscal period: the source is Senesco’s FY2014 10-K, not an Eloxx Pharmaceuticals 2013 Q4 filing.
- Reconcile the conflicting cash-runway disclosures and assess the company’s financing needs and going-concern status.
- Review the complete audited statements and notes for the Fabrus acquisition valuation, purchase accounting, deferred tax liability and subsequent integration costs.
- Verify post-year-end SNS01-T trial updates, dose and safety findings, and any subsequent clinical or regulatory plans.
- Assess dilution and potential warrant/option exercises alongside the company’s fundraising plans and thinly traded OTCQB shares.
- Check the status and economics of the Scripps antibody-platform license, remaining agricultural licenses, and related milestone, royalty or termination obligations.